Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q3 2020 Earnings Presentation
9 slides from Angiodynamics's earnings presentation, Apr 7, 2020
Slide 1: Third Quarter 2020 Earnings Presentation
AngioDynamics Third Quarter 2020 Earnings Presentation April 7, 2020 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c
Slide 3: Third Quarter FY2020 Highlights
Third Quarter FY2020 Highlights Financial Performance Product Family Year-over-Year Sales Growth Vascular Interventions and Therapies (in millions) Q3 FY20 Q3 FY19 Change AngioVac® 44% Revenue $69.8 $65.5 6.5% Thrombolytic 24% Core Peripheral 9% Revenue Excluding Asclera $69.8 $63.9 9.3% Venous Insu
Slide 4: Third Quarter FY2020 Results (unaudited)
Third Quarter FY2020 Results (unaudited) FY2020 FY2019 FY2020 FY2019 $ in thousands (except per share data) Q3 Results Q3 Results Change YTD Results YTD Results Change Revenue $69,780 $65,524 6.5%* $205,825 $199,451 3.2%* Vascular Interventions and Therapies 30,552 29,298 4.3%* 90,616 88,870 2.0%* V
Slide 5: COVID-19 Risk Factor (included in the February 29, 2020 10-Q)
COVID-19 Risk Factor (included in the February 29, 2020 10-Q) We are dependent on the proper functioning of our critical facilities, our supply chain and distribution networks and our sales force as well as the financial stability of our customers, all of which could be negatively impacted by the co
Slide 6: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 6
Slide 7: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Amounts in thousands (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. (2) Deferred financing fees related to the o
Slide 8: Reconciliation of Net Loss to Adjusted EBITDA
Reconciliation of Net Loss to Adjusted EBITDA Amounts in thousands 8
Slide 9: Growth through Focus Execution Accountability
Growth through Focus Execution Accountability 9